ImmunityBio reports preliminary FY2025 ANKTIVA revenue ~$113M, up ~700% YoY, and Saudi approval for NSCLC

ImmunityBio, Inc.

2025-FY EPS reported -$0.38 revenue$113,288,000

Preliminary FY2025 net product revenue ~$113.0M, ~700% YoY increase; Q4 2025 revenue ~$38.3M, up 20% QoQ and 431% YoY.
ANKTIVA unit sales volume grew 750% in 2025 vs 2024; quarter-over-quarter unit growth 54% during FY2025.
Saudi FDA approved ANKTIVA + checkpoint inhibitor for metastatic NSCLC (first global approval for this indication) and + BCG for NMIBC CIS.
Phase 2b QUILT-2.005 trial enrollment ahead of expectations; full enrollment anticipated in H1 2026.
Estimated cash, cash equivalents and marketable securities of $242.8M as of Dec 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.